check_circleStudy Completed

Magnetic Resonance Imaging, Liver Neoplasms

Bayer Identifier:

91106

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
MRI study to evaluate 0.025 mmol/kg BW Gd-EOB-DTPA (SH L 569 B) and 0.05 mmol/kg BW Gd-BOPTA (Gadobenate Dimeglumine) in patients with known or suspected focal liver lesions

Trial purpose

Please see attached Study Results Summary below.

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal
298
Trial Dates
October 2002 - March 2003
Phase
Phase 3
Could I Receive a placebo
N/A
Products
Eovist/Primovist (Gadoxetate disodium, BAY86-4873)
Accepts Healthy Volunteer
N/A

Primary Outcome

Secondary Outcome

Trial design

Multicenter, double-blind, randomized, inter-individual comparison study in MRI with a corresponding blinded reading to evaluate 0.025 mmol/kg BW Gd-EOB-DTPA (SH L 569 B) and 0.05 mmol/kg BW Gd-BOPTA (gadobenate dimeglumine) after a single i.v. injection
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here to find results for studies related to marketed products.